---
schema_version: "secwatch.filing_event.v1"
accession: "0001285550-23-000010"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2023-01-11T23:59:59+00:00"
generated_at: "2026-06-20T16:26:28.171601+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q4 revenue $5.2M (+21%); FY2022 revenue $20.6M (+26%) missing guidance; FY2023 guide $25-27M

## Summary
- Preliminary Q4 2022 revenue $5.2M (+21% YoY); biologics/drug delivery $2.3M (+37%); functional neurosurgery $2.3M (+7%).
- Full year 2022 revenue $20.6M (+26% YoY), below guidance of $21-22M; cash burn $3.0M in Q4; cash $37.5M at year-end.
- FY2023 revenue guidance $25-27M (22-31% growth); backlog at highest level; CEO cites Q4 timing issues.
- Key upcoming milestones: PTC BLA submission for Upstaza, PRISM laser system commercial launch, 10 new centers, 8 FDA submissions.
- Added multiple new biologics/drug delivery partners, total >50; 11 new centers installed in 2022.

## SEC filing metadata
- accession: 0001285550-23-000010
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2023-01-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000128555023000010/0001285550-23-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000128555023000010/clpt-20230111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001285550-23-000010
- JSON: https://secwatch.observer/filing/0001285550-23-000010.json
- Plain text: https://secwatch.observer/filing/0001285550-23-000010.txt

## Key facts
- Earnings Releases
  ClearPoint Neuro, Inc. reported the fourth fiscal quarter ended December 31, 2022 results: revenue $5.2 million.
  - Period: the fourth fiscal quarter ended December 31, 2022
  - Revenue: $5.2 million
  - Result: preliminary results
  source text: financial results for its fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Preliminary Unaudited Financial Highlights • Preliminary unaudited revenue of $5.2 million, a 21% year-over-year increase; • Increased biologics and drug delivery revenue to $2.3 million, a 37% year-over-year increase; • Increased functional neurosurgery products and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285550/000128555023000010/0001285550-23-000010-index.htm
- Earnings Releases
  ClearPoint Neuro, Inc. reported full year ended December 31, 2022 results: revenue $20.6 million. Guidance initiated.
  - Period: full year ended December 31, 2022
  - Revenue: $20.6 million
  - Guidance: initiated
  - Result: preliminary results
  source text: cash equivalents, and short-term investments at December 31, 2022. Full Year 2022 Preliminary Unaudited Financial Highlights • Achieved preliminary unaudited record revenue of $20.6 million, a 26% year-over-year increase, versus most recent guidance of $21.0 - $22.0 million; • Increased biologics and drug delivery revenue to $9.1 million, a 34% year-over-year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285550/000128555023000010/0001285550-23-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.